Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report

Affiliations

¹ Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
² Pharmacy Department, 12 de Octubre University Hospital, Madrid, Spain.

Case Reports

Jorge Arroyo-Andrés et al. Int J Dermatol. 2022 Jul.

. 2022 Jul;61(7):e267-e269.

doi: 10.1111/ijd.15834. Epub 2021 Aug 7.

¹ Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
² Pharmacy Department, 12 de Octubre University Hospital, Madrid, Spain.

No abstract available

References

1. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.
1. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. Blood 2011; 118: 4024-4035.
1. Vonderheid E, Sajjadian A, Kadin M. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-481.
1. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555-566.
1. Hoffmann J, Soliman M, Koch J, et al. Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin. J Eur Acad Dermatol Venereol 2020; 34: e626-e628.